Open AccessReduced Immunogenicity of Intraparenchymal Delivery of Adeno-Associated Virus Serotype 2 Vectors: Brief Overview
Author(s) -
WuhLiang Hwu,
Shinichi Muramatsu,
Bruria Gidoni-Ben-Zeev
Publication year - 2022
Publication title -
current gene therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.704
H-Index - 71
eISSN - 1875-5631
pISSN - 1566-5232
DOI - 10.2174/1566523221666210922155413
Subject(s) - adeno associated virus , immunogenicity , genetic enhancement , vector (molecular biology) , virology , immune system , serotype , gene delivery , medicine , virus , viral vector , immunology , biology , gene , recombinant dna , biochemistry
: Pre existing immunity to Adeno-Associated Virus (AAV) poses a concern in AAV vector–mediated gene therapy. Localized administration of low doses of carefully chosen AAV serotypescan mitigate the risk of an immune response. This article will illustrate the low risk of immuneresponse to AAV serotype 2 vector–mediated gene therapy to the brain with support fromclinical trial data in aromatic L-amino acid decarboxylase deficiency and Parkinson disease.